Abbvie Inc

NYSE:ABBV   9:58:29 AM EDT
117.30
-1.57 (-1.32%)
Mergers / Acquisitions

Abbvie Exercises Right To Acquire Teneoone And Lead Asset Tnb-383B For The Potential Treatment Of Relapsed Or Refractory Multiple Myeloma

Published: 06/24/2021 12:11 GMT
Abbvie Inc (ABBV) - Abbvie Exercises Right to Acquire Teneoone and Lead Asset Tnb-383b for the Potential Treatment of Relapsed Or Refractory Multiple Myeloma.
Abbvie Inc - Exercised Exclusive Right to Acquire Teneoone and Tnb-383b Based on an Interim Analysis of an Ongoing Phase 1 Study.